Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
95.24%
-
Total 13F principal
-
$264,062,863
-
Principal change
-
+$6,379,826
-
Total reported market value
-
$250,352,690
-
Number of holders
-
21
-
Value change
-
+$9,068,361
-
Number of buys
-
11
-
Number of sells
-
17
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q4 2024
As of 31 Dec 2024,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
21 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$264,062,863
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, D. E. Shaw & Co., Inc., WOLVERINE ASSET MANAGEMENT LLC, Graham Capital Management, L.P., Voya Investment Management LLC, Point72 Asset Management, L.P., OAKTREE CAPITAL MANAGEMENT LP, SSI INVESTMENT MANAGEMENT LLC, Affinity Asset Advisors, LLC, and CAPSTONE INVESTMENT ADVISORS, LLC.
This page lists
21
institutional bondholders reporting positions
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.